Lupin's LMS and PolyPeptide Form Alliance to Strengthen Peptide Supply

Lupin Manufacturing Solutions (LMS), a subsidiary of Lupin Limited, announced a major strategic alliance today with PolyPeptide Group AG, marking a significant move in the expanding peptide market.

The long-term partnership aims to build a stronger, more reliable supply chain for peptide-based active pharmaceutical ingredients as demand accelerates worldwide, especially in metabolic disease therapies.

The collaboration focuses on expanding sourcing options, tightening procurement and supply planning, and ensuring dependable, high-quality peptide production across global markets. By joining forces, both companies expect to raise operational efficiency and strengthen readiness for next-generation peptide therapeutics.

Also Read: How a Culture of Thanks Fuels Retention in Hospitals

For LMS, this alliance supports its vision of becoming a leading CDMO partner for both innovator and generic peptide materials. For PolyPeptide, it reinforces its position as a trusted supplier with deeper supply chain flexibility and capacity to manage growing commercial demand.

Dr. Abdelaziz Toumi, chief executive officer, Lupin Manufacturing Solutions, said, “We are delighted to announce our strategic alliance with PolyPeptide. As peptide-based therapies continue to transform the treatment landscape for metabolic and other chronic conditions, LMS is committed to ensuring reliable access to specialized materials that support large-scale commercial production. This underscores our mission to establish secure, agile, and future-ready supply pathways for innovators worldwide.”

Stephane Varray, chief commercial officer, PolyPeptide, added, “Reliability is a competitive advantage in our industry. Working with Lupin Manufacturing Solutions gives us the flexibility and supply chain depth needed to support growing customer demand, including preparations for large-scale metabolics. When you’re enabling life-changing therapies, your supply chain must operate as a true strategic capability.”